Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Mizuho Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by analysts at Mizuho from $205.00 to $250.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s target price would indicate a potential upside of 102.74% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Chardan Capital upped their target price on shares of Palvella Therapeutics from $174.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Cantor Fitzgerald increased their price target on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a research note on Tuesday. Finally, HC Wainwright increased their target price on Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $176.44.

Palvella Therapeutics Stock Up 2.4%

PVLA stock traded up $2.90 during trading on Wednesday, reaching $123.31. The company’s stock had a trading volume of 202,786 shares, compared to its average volume of 285,922. The company’s fifty day moving average is $92.05 and its 200-day moving average is $78.51. The company has a market capitalization of $1.46 billion, a P/E ratio of -46.89 and a beta of -0.16. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $127.69.

Insider Buying and Selling

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC bought a new position in Palvella Therapeutics in the third quarter worth approximately $33,949,000. Summit Partners Public Asset Management LLC boosted its position in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares in the last quarter. Federated Hermes Inc. purchased a new position in Palvella Therapeutics in the third quarter valued at about $21,255,000. Vanguard Group Inc. grew its stake in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after purchasing an additional 330,847 shares during the last quarter. Finally, State Street Corp raised its holdings in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics News Roundup

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA topline: the trial met its primary endpoint (mean mLM-IGA +2.13, p<0.001), showed 95% of evaluable patients ≥6 improved and 86% “Much/Very Much Improved,” reported favorable safety (no drug‑related serious AEs) and plans an NDA submission in H2 2026 with potential U.S. approval in H1 2027 — a clear commercial catalyst if the FDA path proceeds. GlobeNewswire: SELVA Topline Results
• Positive Sentiment: Analyst upgrades/targets: BTIG raised its price target to $215 (buy) and Chardan to $210 (buy), signaling strong Street conviction and sizable upside vs. current levels — this adds buying pressure and institutional interest. Benzinga: BTIG Price Target The Fly: Chardan Price Target
• Neutral Sentiment: Market/technical coverage: multiple outlets note heavy momentum and the stock clearing its 50‑day moving average after the data — these pieces reflect trading dynamics rather than new fundamental information. MSN: Technical Momentum
• Negative Sentiment: Proposed public offering announced — expected to raise capital but introduces potential share dilution, which can offset enthusiasm from the trial news depending on deal size and timing. Business Insider: Proposed Public Offering
• Negative Sentiment: Insider activity shows multiple recent insider sales (7 sales, no purchases reported recently), which can weigh on sentiment even as fundamentals improve. Monitor size/timing of further insider moves. QuiverQuant: Phase 3 Results & Insider Data

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.